NICE vs. TEVA
NICE (NICE Ltd.) and TEVA (Teva Pharmaceutical Industries Limited) are both stocks. NICE operates in Software - Application (Technology), while TEVA operates in Drug Manufacturers - Specialty & Generic (Healthcare). Over the past 10 years, NICE returned 4.08%/yr vs -4.15%/yr for TEVA. At a 0.24 correlation, their price movements are largely independent.
Performance
NICE vs. TEVA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NICE achieves a -19.19% return, which is significantly lower than TEVA's 6.57% return. Over the past 10 years, NICE has outperformed TEVA with an annualized return of 4.08%, while TEVA has yielded a comparatively lower -4.15% annualized return.
NICE
- 1D
- -1.92%
- 1M
- -1.49%
- YTD
- -19.19%
- 6M
- -13.59%
- 1Y
- -48.30%
- 3Y*
- -24.93%
- 5Y*
- -16.72%
- 10Y*
- 4.08%
TEVA
- 1D
- -2.72%
- 1M
- -6.91%
- YTD
- 6.57%
- 6M
- 17.40%
- 1Y
- 87.17%
- 3Y*
- 65.55%
- 5Y*
- 25.39%
- 10Y*
- -4.15%
NICE vs. TEVA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NICE NICE Ltd. | -19.19% | -33.44% | -14.87% | 3.75% | -36.66% | 7.07% | 82.75% | 43.38% | 17.73% | 33.92% |
TEVA Teva Pharmaceutical Industries Limited | 6.57% | 41.61% | 111.11% | 14.47% | 13.86% | -16.99% | -1.53% | -36.45% | -18.63% | -46.18% |
Correlation
The correlation between NICE and TEVA is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.07 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.21 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jan 25, 1996 | 0.24 |
The correlation between NICE and TEVA shifts across timeframes, from 0.07 (1 year) to 0.24 (all time), reflecting how their relationship changes across market environments.
Fundamentals
NICE:
$5.54B
TEVA:
$39.21B
NICE:
$8.49
TEVA:
$1.34
NICE:
10.76
TEVA:
24.87
NICE:
0.33
TEVA:
0.19
NICE:
1.89
TEVA:
2.24
NICE:
1.51
TEVA:
4.76
NICE:
$3.01B
TEVA:
$17.35B
NICE:
$1.98B
TEVA:
$9.03B
NICE:
$841.27M
TEVA:
$3.05B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NICE vs. TEVA — Risk / Return Rank
NICE
TEVA
NICE vs. TEVA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NICE Ltd. (NICE) and Teva Pharmaceutical Industries Limited (TEVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NICE | TEVA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.21 | ||
| Sortino ratioReturn per unit of downside risk | -4.72 | ||
| Omega ratioGain probability vs. loss probability | 0.81 | 1.43 | -0.62 |
| Calmar ratioReturn relative to maximum drawdown | -0.94 | 4.02 | -4.96 |
| Martin ratioReturn relative to average drawdown | -1.50 | 10.94 | -12.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NICE | TEVA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.95 | 2.25 | -3.21 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.42 | 0.59 | -1.02 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.12 | -0.09 | +0.21 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.23 | 0.31 | -0.08 |
Drawdowns
NICE vs. TEVA - Drawdown Comparison
The maximum NICE drawdown since its inception was -93.23%, roughly equal to the maximum TEVA drawdown of -90.89%. Use the drawdown chart below to compare losses from any high point for NICE and TEVA.
Loading charts...
Drawdown Indicators
| NICE | TEVA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.23% | -90.89% | -2.34% |
Max Drawdown (1Y)Largest decline over 1 year | -51.56% | -21.79% | -29.77% |
Max Drawdown (3Y)Largest decline over 3 years | -66.98% | -43.70% | -23.28% |
Max Drawdown (5Y)Largest decline over 5 years | -72.58% | -43.70% | -28.88% |
Max Drawdown (10Y)Largest decline over 10 years | -72.58% | -88.41% | +15.83% |
Current DrawdownCurrent decline from peak | -71.00% | -50.84% | -20.16% |
Average DrawdownAverage peak-to-trough decline | -35.17% | -32.00% | -3.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 32.15% | 8.00% | +24.15% |
Volatility
NICE vs. TEVA - Volatility Comparison
NICE Ltd. (NICE) has a higher volatility of 12.47% compared to Teva Pharmaceutical Industries Limited (TEVA) at 9.18%. This indicates that NICE's price experiences larger fluctuations and is considered to be riskier than TEVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NICE | TEVA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.47% | 9.18% | +3.29% |
Volatility (6M)Calculated over the trailing 6-month period | 41.62% | 23.54% | +18.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 50.86% | 38.97% | +11.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.81% | 42.94% | -3.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.23% | 47.34% | -14.11% |
Dividends
NICE vs. TEVA - Dividend Comparison
Neither NICE nor TEVA has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NICE NICE Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.14% | 0.76% | 0.91% |
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Financials
NICE vs. TEVA - Financials Comparison
This section allows you to compare key financial metrics between NICE Ltd. and Teva Pharmaceutical Industries Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NICE vs. TEVA - Profitability Comparison
NICE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NICE Ltd. reported a gross profit of 493.46M and revenue of 766.53M. Therefore, the gross margin over that period was 64.4%.
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.
NICE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NICE Ltd. reported an operating income of 126.41M and revenue of 766.53M, resulting in an operating margin of 16.5%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.
NICE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NICE Ltd. reported a net income of 46.69M and revenue of 766.53M, resulting in a net margin of 6.1%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.
Frequently Asked Questions
NICE and TEVA have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NICE has higher volatility (12.47%) compared to TEVA (9.18%). In terms of maximum drawdown, NICE dropped -93.23% vs TEVA's -90.89%.
TEVA currently has the higher Sharpe Ratio (2.25 vs -0.95), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NICE and TEVA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer